These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
336 related articles for article (PubMed ID: 24094552)
21. The influence of blood phenylalanine levels on neurocognitive function in adult PKU patients. Bartus A; Palasti F; Juhasz E; Kiss E; Simonova E; Sumanszki C; Reismann P Metab Brain Dis; 2018 Oct; 33(5):1609-1615. PubMed ID: 29948654 [TBL] [Abstract][Full Text] [Related]
22. [Magnetic resonance imaging of the brain in phenylketonuria]. Izumi M; Yamazaki H; Nakabayashi H; Owada M No To Hattatsu; 2006 Jan; 38(1):27-31. PubMed ID: 16447793 [TBL] [Abstract][Full Text] [Related]
23. Magnetic resonance imaging in phenylketonuria: reversal of cerebral white matter change. Cleary MA; Walter JH; Wraith JE; White F; Tyler K; Jenkins JP J Pediatr; 1995 Aug; 127(2):251-5. PubMed ID: 7636650 [TBL] [Abstract][Full Text] [Related]
24. Blood-brain phenylalanine relationships in persons with phenylketonuria. Koch R; Moats R; Guttler F; Guldberg P; Nelson M Pediatrics; 2000 Nov; 106(5):1093-6. PubMed ID: 11061780 [TBL] [Abstract][Full Text] [Related]
25. Neurocognitive functioning in adults with phenylketonuria: results of a long term study. Weglage J; Fromm J; van Teeffelen-Heithoff A; Möller HE; Koletzko B; Marquardt T; Rutsch F; Feldmann R Mol Genet Metab; 2013; 110 Suppl():S44-8. PubMed ID: 24071437 [TBL] [Abstract][Full Text] [Related]
26. Effect of high-protein meal plus aspartame ingestion on plasma phenylalanine concentrations in obligate heterozygotes for phenylketonuria. Curtius HC; Endres W; Blau N Metabolism; 1994 Apr; 43(4):413-6. PubMed ID: 8159095 [TBL] [Abstract][Full Text] [Related]
28. [Brain white matter lesions of children with phenylketonuria before and after treatment]. Wang ZX; Zhou ZS; Yu WM Zhongguo Dang Dai Er Ke Za Zhi; 2006 Feb; 8(1):13-6. PubMed ID: 16522231 [TBL] [Abstract][Full Text] [Related]
29. The Effects of Breastfeeding in Infants With Phenylketonuria. Kose E; Aksoy B; Kuyum P; Tuncer N; Arslan N; Ozturk Y J Pediatr Nurs; 2018; 38():27-32. PubMed ID: 29167077 [TBL] [Abstract][Full Text] [Related]
30. Assessment of tetrahydrobiopterin (BH4) responsiveness in phenylketonuria. Fiege B; Blau N J Pediatr; 2007 Jun; 150(6):627-30. PubMed ID: 17517248 [TBL] [Abstract][Full Text] [Related]
31. Volumetric brain reductions in adult patients with phenylketonuria and their relationship with blood phenylalanine levels. Pardo J; Capdevila-Lacasa C; Segura B; Pané A; Montserrat C; de Talló Forga-Visa M; Moreno PJ; Garrabou G; Grau-Junyent JM; Junqué C; J Neurodev Disord; 2024 Jun; 16(1):33. PubMed ID: 38907189 [TBL] [Abstract][Full Text] [Related]
32. NOX, the main regulator in oxidative stress in experimental models of phenylketonuria? He Y; Gu X; Lu L; Liang L; Gao J; Zhang X J Pediatr Endocrinol Metab; 2013; 26(7-8):675-82. PubMed ID: 23612646 [TBL] [Abstract][Full Text] [Related]
34. Optimising growth in phenylketonuria: current state of the clinical evidence base. Dokoupil K; Gokmen-Ozel H; Lammardo AM; Motzfeldt K; Robert M; Rocha JC; van Rijn M; Ahring K; Bélanger-Quintana A; MacDonald A Clin Nutr; 2012 Feb; 31(1):16-21. PubMed ID: 21959353 [TBL] [Abstract][Full Text] [Related]
35. Long-term follow-up of patients treated for phenylketonuria (PKU). Results from the Prague PKU Center. Cechák P; Hejcmanová L; Rupp A Eur J Pediatr; 1996 Jul; 155 Suppl 1():S59-63. PubMed ID: 8828612 [TBL] [Abstract][Full Text] [Related]
36. The pathogenesis of the white matter abnormalities in phenylketonuria. A multimodal 3.0 tesla MRI and magnetic resonance spectroscopy (1H MRS) study. Leuzzi V; Tosetti M; Montanaro D; Carducci C; Artiola C; Carducci C; Antonozzi I; Burroni M; Carnevale F; Chiarotti F; Popolizio T; Giannatempo GM; D'Alesio V; Scarabino T J Inherit Metab Dis; 2007 Apr; 30(2):209-16. PubMed ID: 17245558 [TBL] [Abstract][Full Text] [Related]
37. Nitric oxide synthase inhibition and oxidative stress in cardiovascular diseases: possible therapeutic targets? Rochette L; Lorin J; Zeller M; Guilland JC; Lorgis L; Cottin Y; Vergely C Pharmacol Ther; 2013 Dec; 140(3):239-57. PubMed ID: 23859953 [TBL] [Abstract][Full Text] [Related]
38. Key European guidelines for the diagnosis and management of patients with phenylketonuria. van Spronsen FJ; van Wegberg AM; Ahring K; Bélanger-Quintana A; Blau N; Bosch AM; Burlina A; Campistol J; Feillet F; Giżewska M; Huijbregts SC; Kearney S; Leuzzi V; Maillot F; Muntau AC; Trefz FK; van Rijn M; Walter JH; MacDonald A Lancet Diabetes Endocrinol; 2017 Sep; 5(9):743-756. PubMed ID: 28082082 [TBL] [Abstract][Full Text] [Related]
39. Cerebral glucose metabolism is decreased in white matter changes in patients with phenylketonuria. Hasselbalch S; Knudsen GM; Toft PB; Høgh P; Tedeschi E; Holm S; Videbaek C; Henriksen O; Lou HC; Paulson OB Pediatr Res; 1996 Jul; 40(1):21-4. PubMed ID: 8798240 [TBL] [Abstract][Full Text] [Related]
40. Clinical significance of brain phenylalanine concentration assessed by in vivo proton magnetic resonance spectroscopy in phenylketonuria. Leuzzi V; Bianchi MC; Tosetti M; Carducci CL; Carducci CA; Antonozzi I J Inherit Metab Dis; 2000 Sep; 23(6):563-70. PubMed ID: 11032331 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]